Kenzo Okada

Synchronous bilateral noninvasive ductal carcinoma of the male breast: a case report.

A 45-year-old man developed a bloody discharge from his right nipple. Physical examination revealed bloody discharge from his left nipple also but no swelling, breast mass, or axillary lymph nodes. He then underwent bilateral total glandectomy without axillary dissection. Histological examination revealed low-grade ductal carcinomain situ (DCIS) with a low-papillary and cribriform pattern measuring about 4 mm in diameter in the breast bilaterally. To our knowledge, this is the first report of synchronous bilateral DCIS in a male. Since this patient’s hormonal profile showed a relatively high blood level of prolactin, the causative relationship between hyperprolactinemia and male breast cancer is discussed. Including our case, 5 of 6 cases reported thus far have been bilateral, and 4 of the 6 cases have been synchronous. We emphasize that the contralateral breast should also be tested or followed in male breast cancer patients with hyperprolactinemia.

Laminin Levels and Stage of Vascular Invasion as Predictive Factors of Liver Metastasis in Colon Cancer

The glycoprotein laminin mediates the adhesion of tumor cells to the basement membrane prior to invasion. In this study, we determined the laminin levels of the peripheral and returned venous blood in 46 colon cancer patients without detectable liver metastasis. The laminin levels of both peripheral and returned blood were significantly higher in the cases with vascular invasion compared to the group without it. However, no correlation was observed between the stage of vascular invasion and laminin levels.

Evaluation of Combination Chemotherapy Using 5-FU, Leucovorin, and CDDP (FLP Therapy) Against Recurrent or Advanced Stomach Cancer

Between July 1991 and October 1992, we performed combination chemotherapy consisting of 5-FU, leucovorin, and CDDP (FLP therapy) against recurrent or advanced stomach cancer. The outcome was CR in 1, PR in 7, NC in 2, and PD in 11 of the 1 levaluable patients, resulting in an overall response rate of 72.7%. Performance status was improved in all patients. All toxicities were grade 3 or below. Consequently, FLP therapy was, hereafter, expected to be safety and effective against recurrent and advanced stomach cancer, and to improve the QOL.